Haohai Life Sciences: Plan to acquire the remaining 20% equity of a non-wholly-owned subsidiary for 74 million yuan.

Haohai Life Sciences announced on November 9th that its wholly-owned subsidiary, Shanghai Haohai Medical Technology Development Co., Ltd., has entered into a supplementary agreement for the transfer of equity with the transferor. According to this agreement, the transferor has agreed to sell the remaining 20% equity of the target company to the transferee for a price of 74,000,000 yuan. After the acquisition is completed, the group will hold 100% of the equity of the target company.